肝脓肿和呼吸机相关性肺炎患者中高毒力肺炎克雷伯菌的表型和遗传特征。
Phenotypic and genetic characterization of hypervirulent Klebsiella pneumoniae in patients with liver abscess and ventilator-associated pneumonia.
发表日期:2023 Nov 13
作者:
Mingquan Guo, Bo Gao, Jun Su, Yigang Zeng, Zelin Cui, Haodong Liu, XiaoKui Guo, Yongzhang Zhu, Beiwen Wei, Yanan Zhao, Juanxiu Qin, Xiaoye Lu, Qingtian Li
来源:
TROPICAL MEDICINE & INTERNATIONAL HEALTH
摘要:
肺炎克雷伯菌感染引起的呼吸机相关性肺炎(VAP)和化脓性肝脓肿(PLA)可引发危及生命的恶性后果,然而,关于VAP和PLA菌株相关的临床致病机制的研究很少。本研究共纳入 266 名患者进行分析,其中包括 129 名 VAP 和 137 名 PLA。我们对两组肺炎克雷伯菌分离株进行了全面调查,包括表型实验、临床流行病学、基因组分析和仪器分析,即获得导致两种不同感染结果的肺炎克雷伯菌菌株的基因组差异谱。我们发现PLA群体有特定基础疾病的倾向,特别是糖尿病和胆石症。 VAP的耐药水平显着高于PLA(78.57% vs. 36%,P<0.001),而毒力结果相反。两组之间生化过程的关键信号通路也存在一些差异。肺炎克雷伯菌感染中出现的iucA、rmpA、高粘膜粘稠表型和ST23的组合对于及时治疗更为重要和高度谨慎。本研究可能为肺炎克雷伯菌临床筛查、流行病学监测和有效治疗策略提供基准。© 2023。作者。
Ventilator-associated pneumonia (VAP) and pyogenic liver abscess (PLA) due to Klebsiella pneumoniae infection can trigger life-threatening malignant consequences, however, there are few studies on the strain-associated clinical pathogenic mechanisms between VAP and PLA. A total of 266 patients consist of 129 VAP and 137 PLA were included for analysis in this study. We conducted a comprehensive survey for the two groups of K. pneumoniae isolates, including phenotypic experiments, clinical epidemiology, genomic analysis, and instrumental analysis, i.e., to obtain the genomic differential profile of K. pneumoniae strains responsible for two distinct infection outcomes. We found that PLA group had a propensity for specific underlying diseases, especially diabetes and cholelithiasis. The resistance level of VAP was significantly higher than that of PLA (78.57% vs. 36%, P < 0.001), while the virulence results were opposite. There were also some differences in key signaling pathways of biochemical processes between the two groups. The combination of iucA, rmpA, hypermucoviscous phenotype, and ST23 presented in K. pneumoniae infection is more important and highly prudent for timely treatment. The present study may contribute a benchmark for the K. pneumoniae clinical screening, epidemiological surveillance, and effective therapeutic strategies.© 2023. The Author(s).